BriaCell Therapeutics' short interest declined 18.4% in July, with Institutional investors increasing stakes, and HC Wainwright maintaining a "buy" rating.
BriaCell Therapeutics, in Phase 3 trials for advanced breast cancer, saw a 18.4% decline in short interest in July, dropping from 569,400 to 464,400 shares. Institutional investors like National Bank of Canada FI, Onyx Bridge Wealth Group LLC, and K.J. Harrison & Partners Inc increased their stakes during Q4. HC Wainwright maintains a "buy" rating and an $18.00 price target. BCTX reported $0.11 EPS in Q2, exceeding analyst estimates by $0.66.
August 17, 2024
14 Articles